Spread of Covid-19's Delta Variant Will Substantially Up Cas
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
The increased transmissibility associated with the COVID-19’s Delta variant is likely to substantially increase cases and put a greater pressure on healthcare systems, particularly in the contexts of low vaccine coverage, the WHO has warned. In its COVID-19 Weekly Epidemiological Update released on July 13, the World Health Organisation said that an overall rise in COVID-19 cases due to the Delta variant is reported across all WHO regions.

As of July 13, at least 111 countries, territories and areas have reported detection of the Delta variant, and this is expected to continue to increase, becoming the dominant variant globally in the coming months. The increased transmissibility associated with the Delta variant is likely to result in substantial increases in case incidence and greater pressure on healthcare systems, particularly in contexts of low vaccine coverage, it said.

Globally, cases of the Alpha variant have been reported in 178 countries, territories or areas, while 123 countries reported cases of the Beta variant, 75 countries reported cases of the Gamma variant. The update said that the Delta variant has shown higher transmissibility than other Variants of Concerns (VOCs) identified to date.

The increased transmissibility means that it is likely to become the dominant variant globally over the coming months, the update said. Moreover, in large parts of the world, there remain gaps in epidemiological surveillance, testing and genomic sequencing, and this limits our ability to monitor and assess the impact of current and future variants in a timely manner, it said.

The update noted that as countries gradually resume non-essential international travel, the introduction of risk mitigation measures aiming to reduce travel-associated exportation, importation and onward transmission of SARS-CoV-2 should be based on thorough risk assessments conducted systematically and routinely. Almost a quarter of the world’s population has received at least one dose of a COVID-19 vaccine – over three billion doses administered.

The breadth and quality of evidence of the efficacy and effectiveness of current vaccines against emerging variants remains limited. Full vaccination offers high levels of protection against severe disease and death for all four VOCs, with mixed evidence as to the impacts on infection, mild-moderate disease and transmission. Virus evolution and the phenotypic impacts of all variants, including potential immune escape, require close monitoring and assessment.

Dr. T●●●●z H●●●●●●i and 1 others like this3 shares